Mahzi Therapeutics

Advancing precision therapies for rare neurodevelopmental diseases

https://wefunder.com/mahzi.therapeutics

Total raised on Wefunder: 0

Total investors: 0

Quick facts

  • $60M raised from leading VCs: Venrock, HealthCap, Droia Ventures & HBM Partners
  • $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
  • Leadership from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
  • Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
  • CEO with 20+ years at Merck and rare disease pioneers Genzyme & Ultragenyx
  • Now enrolling patients in first-ever gene therapy clinical trial for Pitt Hopkins Syndrome
  • 800+ rare neurogenetic disorders addressable with our approach; targeting a $16B+ market
  • $200-$600M peak annual revenue projected per indication in pipeline (not guaranteed)

Team profiles

Featured investor profiles

Mahzi Therapeutics

Advancing precision therapies for rare neurodevelopmental diseases

Countdown clock
Exclusive
Friends Invest First
Soft Launch Until Jul 1 @ 3:00 AM ET
--
day
--
hour
--
min
--
sec
INVESTMENT TERMS
Preferred Stock
$87.9M pre-money valuation $3.47 per share

What Investors Say

LEAD INVESTOR
Invested $5,000 this round
Mahzi is on a great mission to develop precision genetic therapies for seizure and autism-based disorders in meaningful partnership with patient advocacy groups. Developing targeted genetic therapies for severe, under-served neurodevelopmental disorders like Pitt Hopkins syndrome, WOREE syndrome, and CHD2 deficiency is aligned with critical vision of this company. I’m excited to support Mahzi in moving to the next phase of growth and bringing potential disease-modifying treatments to this very deserving community of patients and families.
What People Say